Products
Platform
Research
Market
Learn
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | 4.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 1.92 | - |
NAV | ₹39.80 | - |
Fund Started | 12 Nov 2018 | - |
Fund Size | ₹3106.92 Cr | - |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | - |
Risk
Very High
-
Rating
4.0
-
Min SIP Amount
₹100
-
Expense Ratio
1.92
-
NAV
₹39.80
-
Fund Started
12 Nov 2018
-
Fund Size
₹3106.92 Cr
-
Exit Load
Exit load of 0.50% if redeemed within 1 month.
-
Returns
1 Year | -2.11% | - |
3 Year | 24.86% | - |
5 Year | 17.86% | - |
1 Year
-2.11%
-
3 Year
24.86%
-
5 Year
17.86%
-
Holding Analysis
Equity | 97.15% | - |
Cash | 2.85% | - |
Equity
97.15%
-
Cash
2.85%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Cipla Ltd. | 9.16% |
Sun Pharmaceutical Industries Ltd. | 7.88% |
Ipca Laboratories Ltd. | 7.56% |
Cohance Lifesciences Ltd. | 7.38% |
Laurus Labs Ltd. | 6.12% |
Gland Pharma Ltd. | 5.55% |
Apollo Hospitals Enterprise Ltd. | 4.77% |
Globus Medical Inc | 4.66% |
Illumina Inc. (USA) | 4.53% |
Sai Life Sciences Ltd. | 4.52% |
-
Fund Manager
Name | Jay Kothari | - |
Start Date | 16 Mar 2018 | - |
Name
Jay Kothari
-
Start Date
16 Mar 2018
-
About Fund
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | - |
Launch Date | 12 Nov 2018 | - |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
-
Launch Date
12 Nov 2018
-
